Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.49 |
| ▸ | CCR2 | P41597 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13439733 | 1.00 | OPRK1 (0.53) | OPRK1FFAR1MCHR1ROCK1ROCK2 | |
| SCHEMBL13439728 | 0.93 | ROCK1 (0.58) | OPRK1FFAR1MCHR1ROCK1ROCK2 | |
| SCHEMBL13439723 | 0.93 | ROCK1 (0.58) | OPRK1FFAR1MCHR1ROCK1ROCK2 | |
| SCHEMBL13439730 | 0.93 | OPRK1 (0.61) | OPRK1ROCK1ROCK2CCR2GAA | |
| SCHEMBL69885 | 0.88 | FFAR1 (0.64) | OPRK1FFAR1ROCK1ROCK2CCR2 | |
| Hydrochloric Acid SCHEMBL10608022 | 0.87 | FFAR1 (0.63) | OPRK1FFAR1ROCK1ROCK2CCR2 | |
| SCHEMBL13462928 | 0.84 | OPRK1 (0.56) | OPRK1FFAR1MCHR1ROCK1ROCK2 | |
| SCHEMBL10605824 | 0.84 | BCHE (0.56) | OPRK1MCHR1ROCK1ROCK2CCR2 | |
| SCHEMBL10607225 | 0.84 | OPRK1 (0.56) | OPRK1FFAR1MCHR1ROCK1ROCK2 | |
| SCHEMBL10606014 | 0.84 | SIGMAR1 (0.60) | OPRK1MCHR1ROCK1ROCK2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | OPRK1 416/4885FFAR1 112/4885MCHR1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.